EGFR and neoplasm: In a phase II trial where avelumab was given in addition to chemotherapy and EGFR-targeted therapy in a cohort of patients with predominantly microsatellite-stable metastatic colorectal cancer, we identified three patients with emerging tumor subclones on avelumab treatment that harbored PD-L1 sequence variants (11).